Laurus Labs Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) for anti-etrovirals (ARVs), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology. The company develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) and contract development and manufacturing organisation (CDMO) to the global pharmaceutical companies. It also produces specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals.
The company’s business units include generics APIs, generics finished dosage forms (FDFs), and synthesis and ingredients. Its generics APIs business comprises the development, manufacture and sale of APIs and advanced intermediates in the ARV, Hepatitis C, oncology, cardiovascular, anti-diabetic, anti-asthmatic, gastroenterology and ophthalmic therapeutic areas. The generics FDFs is engaged in developing and manufacturing oral solid formulations.
The pharmaceutical industry is considered to be one of the fastest growing industries in the world and is also the biggest contributor to world economy. Due to increased overall use of treatments and costlier specialty therapies, global spending on prescription medicines is expected to increase between 2-5 per cent annually over a period of next five years from USD 955 billion reported for the previous year and may exceed USD 1.1 trillion overall by 2024. Despite this, the industry may experience sluggish growth for the next five years compared to the previous five years because of the corona virus pandemic’s impact.
You can read up to 3 premium stories before you subscribe to Magzter GOLD
Log in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines
READ THE ENTIRE ISSUE
August 03 - 16, 2020